[1]Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386(9990):281-91.[2]Floyd CN, Ferro A. Indications for anticoagulant and antiplatelet combined therapy. BMJ. 2017;359:j3782.[3]Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost. 2007;5 Suppl 1:255-63.[4]Benz AP, Johansson I, Dewilde WJM, Lopes RD, Mehran R, Sartori S, et al. Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. Eur Heart J Cardiovasc Pharmacother. 2022;8(7):648-59.[5]De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev. 2012;2012(9):CD001342.[6]Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004(4):CD000187.[7]Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol. 2020;5(5):582-9.[8]Paikin JS, Wright DS, Eikelboom JW. Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Rev. 2011;25(3):123-9. 更多神经科临床知识哪里看? 快来“医生站”瞧一瞧👇